花旗:擴大港股通範圍帶動港交所(0388.HK)收入 維持對其積極看法
花旗發表研究報告出,港交所(0388.HK)擴大港股通範圍,預計隨着未來符合條件的科創板和生物技術公司的增多,港交所的潛在收入將會擴大,維持對港交所積極的看法。
花旗報告指出,目前只有10只科創板股票和7家生物技術公司符合進入港股通的要求,預計對港交所的盈利只有低個位數的影響,估計MSCIA股指數期貨將會很快獲批。
港交所行政總裁李小加早前指出,第二上市股份納入港股通在議程中,惟仍需時落實。港交所預計,明年初擴大滬深港通納入科創板股票。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.